PTGS2 and metabolic dysfunction-associated steatohepatitis: Activation of TGR5 significantly inhibits the mRNA levels of inducible nitric oxide synthase (iNOS), monocyte chemoattractant protein-1 (MCP-1), cyclooxygenase-2 (COX-2), interleukin-6 (IL-6), and other pro-inflammatory factors, thus alleviating the development of NASH (Wang Y. D. et al., 2011).